POLBF (Poolbeg Pharma) Accounts Payable: $0.20 Mil (As of Dec. 2025)


What is Poolbeg Pharma Accounts Payable?

Poolbeg Pharma POLBF Accounts Payable is $0.20 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Poolbeg Pharma's Accounts Payable for the quarter that ended in Dec. 2025 was $0.20 Mil.

Poolbeg Pharma's quarterly Accounts Payable increased from Dec. 2024 ($0.21 Mil) to Jun. 2025 ($0.58 Mil) but then declined from Jun. 2025 ($0.58 Mil) to Dec. 2025 ($0.20 Mil).

Poolbeg Pharma's annual Accounts Payable increased from Dec. 2023 ($0.10 Mil) to Dec. 2024 ($0.21 Mil) but then declined from Dec. 2024 ($0.21 Mil) to Dec. 2025 ($0.20 Mil).

Poolbeg Pharma Accounts Payable Related Terms

Poolbeg Pharma Accounts Payable Historical Data

* Premium members only.

The historical data trend for Poolbeg Pharma's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poolbeg Pharma Accounts Payable Chart

Poolbeg Pharma Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
0.11 0.36 0.10 0.21 0.20

Poolbeg Pharma Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Accounts Payable Get a 7-Day Free Trial Premium Member Only 0.10 0.71 0.21 0.58 0.20

Poolbeg Pharma Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $0.20 Mil mean?
Poolbeg Pharma (POLBF) has a Accounts Payable of $0.20 Mil as of Dec. 2025. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Poolbeg Pharma and its competitors.
Is Poolbeg Pharma's Accounts Payable too high?
Poolbeg Pharma's current Accounts Payable is $0.20 Mil.
How does Poolbeg Pharma's Accounts Payable compare to VRTX and REGN?
Poolbeg Pharma's Accounts Payable of $0.20 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Poolbeg Pharma and its competitors. Poolbeg Pharma's current Accounts Payable is $0.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poolbeg Pharma stock overvalued right now?
Poolbeg Pharma (POLBF) has a current Accounts Payable of $0.20 Mil. The current Accounts Payable is $0.20 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Poolbeg Pharma (POLBF), the current Accounts Payable is $0.20 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Poolbeg Pharma Business Description

Other Exchanges POLB:UK7JN:Germany
Address 20 St. Andrew Street, The Clubhouse Holborn, London, GBR, EC4A 3AG
Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's main asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). The group is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's markets. It is focused on partnering its high-value programmes that are targeting large markets and addressing critical unmet medical needs.